Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

VEGF as a target

VEGF as a target Since 1971, when Judah Folkman postulated that tumor progression relies on the tumor’s ability to meet its requirements in oxygen and nutriments by releasing so-called tumor angiogenic factors (TAF), most researchers working in the growth factor field have been searching for TAF. Today, almost 50 angiogenic growth factors have been discovered, but only one has proven its role in tumor angiogenesis. In 1989, the purification of a growth factor specific for endothelial vascular cells, called vascular endothelial growth factor (VEGF), raised great expectations that it would meet the criteria of the so-called TAF. The prophecy that inhibiting TAF would be sufficient to eradicate the tumor burden has not yet been demonstrated in human tumors. Meanwhile anti-VEGF therapy has proven its efficacy in combination with chemotherapy, and this strategy may be more efficient on patients treated at early stage. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

VEGF as a target

Ropert, Stanislas; Plouët, Jean
Targeted Oncology , Volume 1 (4) – Oct 11, 2006
Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/vegf-as-a-target-f6X5LWjGIM

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2006 by Springer-Verlag
Subject
Medicine & Public Health; Biomedicine general; Oncology
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-006-0027-0
Publisher site
See Article on Publisher Site

Abstract

Since 1971, when Judah Folkman postulated that tumor progression relies on the tumor’s ability to meet its requirements in oxygen and nutriments by releasing so-called tumor angiogenic factors (TAF), most researchers working in the growth factor field have been searching for TAF. Today, almost 50 angiogenic growth factors have been discovered, but only one has proven its role in tumor angiogenesis. In 1989, the purification of a growth factor specific for endothelial vascular cells, called vascular endothelial growth factor (VEGF), raised great expectations that it would meet the criteria of the so-called TAF. The prophecy that inhibiting TAF would be sufficient to eradicate the tumor burden has not yet been demonstrated in human tumors. Meanwhile anti-VEGF therapy has proven its efficacy in combination with chemotherapy, and this strategy may be more efficient on patients treated at early stage.

Journal

Targeted Oncology – Springer Journals

Published: Oct 11, 2006

There are no references for this article.